133 related articles for article (PubMed ID: 1544830)
1. Bioreductive mechanisms.
Workman P
Int J Radiat Oncol Biol Phys; 1992; 22(4):631-7. PubMed ID: 1544830
[TBL] [Abstract][Full Text] [Related]
2. Bioreductive therapies: an overview of drugs and their mechanisms of action.
Rauth AM; Melo T; Misra V
Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):755-62. PubMed ID: 9845091
[TBL] [Abstract][Full Text] [Related]
3. Bioreductive drugs in cancer therapy.
Stratford IJ
BJR Suppl; 1992; 24():128-36. PubMed ID: 1341908
[No Abstract] [Full Text] [Related]
4. Bioreductive therapy.
Chaplin DJ
Int J Radiat Oncol Biol Phys; 1992; 22(4):685-7. PubMed ID: 1544837
[No Abstract] [Full Text] [Related]
5. Bioreductive prodrugs for cancer therapy.
Seddon B; Kelland LR; Workman P
Methods Mol Med; 2004; 90():515-42. PubMed ID: 14657582
[No Abstract] [Full Text] [Related]
6. Hypoxia: targeting the tumour.
Boyle RG; Travers S
Anticancer Agents Med Chem; 2006 Jul; 6(4):281-6. PubMed ID: 16842231
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice.
Lee AE; Wilson WR
Toxicol Appl Pharmacol; 2000 Feb; 163(1):50-9. PubMed ID: 10662604
[TBL] [Abstract][Full Text] [Related]
8. A novel multifunctional 2-nitroimidazole-based bioreductive linker and its application in hypoxia-activated prodrugs.
Huang Y; Jin C; Yu J; Wang L; Lu W
Bioorg Chem; 2020 Aug; 101():103975. PubMed ID: 32474180
[TBL] [Abstract][Full Text] [Related]
9. Assessment of a range of novel nitro-aromatic radiosensitizers and bioreductive drugs.
Fielden EM; Adams GE; Cole S; Naylor MA; O'Neill P; Stephens MA; Stratford IJ
Int J Radiat Oncol Biol Phys; 1992; 22(4):707-11. PubMed ID: 1544842
[TBL] [Abstract][Full Text] [Related]
10. Bioreductive drugs for cancer therapy: the search for tumor specificity.
Adams GE; Stratford IJ
Int J Radiat Oncol Biol Phys; 1994 May; 29(2):231-8. PubMed ID: 8195012
[TBL] [Abstract][Full Text] [Related]
11. [The Oxygen effect: an old new target?].
Lartigau E; Dewas S; Gras L
Cancer Radiother; 2008 Jan; 12(1):42-9. PubMed ID: 18261946
[TBL] [Abstract][Full Text] [Related]
12. [Hypoxic bioreductive agents: the possible immune and receptor-mediated mechanisms of antitumor action].
Shchepetkin IA
Eksp Klin Farmakol; 1999; 62(3):67-74. PubMed ID: 10439954
[TBL] [Abstract][Full Text] [Related]
13. Second-generation 1,2,4-benzotriazine 1,4-di-N-oxide bioreductive anti-tumor agents: pharmacology and activity in vitro and in vivo.
Minchinton AI; Lemmon MJ; Tracy M; Pollart DJ; Martinez AP; Tosto LM; Brown JM
Int J Radiat Oncol Biol Phys; 1992; 22(4):701-5. PubMed ID: 1544841
[TBL] [Abstract][Full Text] [Related]
14. Radiation-activated prodrugs as hypoxia-selective cytotoxins: model studies with nitroarylmethyl quaternary salts.
Wilson WR; Tercel M; Anderson RF; Denny WA
Anticancer Drug Des; 1998 Sep; 13(6):663-85. PubMed ID: 9755724
[TBL] [Abstract][Full Text] [Related]
15. Targeting tumors with hypoxia-activated cytotoxins.
Ahn GO; Brown M
Front Biosci; 2007 May; 12():3483-501. PubMed ID: 17485316
[TBL] [Abstract][Full Text] [Related]
16. Development of hypoxia selective cytotoxins for cancer treatment: an update.
Cerecetto H; González M; Lavaggi ML
Med Chem; 2006 May; 2(3):315-27. PubMed ID: 16948479
[TBL] [Abstract][Full Text] [Related]
17. [Hypoxia: a therapeutic target].
Fernández-Braña M
Clin Transl Oncol; 2005 Dec; 7(11):475-6. PubMed ID: 16373057
[No Abstract] [Full Text] [Related]
18. Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards.
Wilson WR; Hicks KO; Pullen SM; Ferry DM; Helsby NA; Patterson AV
Radiat Res; 2007 Jun; 167(6):625-36. PubMed ID: 17523848
[TBL] [Abstract][Full Text] [Related]
19. 5-Nitro-4-(N,N-dimethylaminopropylamino)quinoline (5-nitraquine), a new DNA-affinic hypoxic cell radiosensitizer and bioreductive agent: comparison with nitracrine.
Wilson WR; Siim BG; Denny WA; van Zijl PL; Taylor ML; Chambers DM; Roberts PB
Radiat Res; 1992 Sep; 131(3):257-65. PubMed ID: 1438685
[TBL] [Abstract][Full Text] [Related]
20. Enzyme-directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase.
Workman P
Oncol Res; 1994; 6(10-11):461-75. PubMed ID: 7620214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
